eLetters

117 e-Letters

published between 2010 and 2013

  • Response
    Marie Condon

    Dear Editor,

    Many thanks for the very interesting letter from Abud-Mendoza, highlighting their work in Mexico where they have successfully used rituximab in the treatment of both lupus nephritis and systemic lupus.
    Their initial report from 2006 [1] used rituximab as a treatment for refractory lupus nephritis and showed very detailed work on lymphocytes after rituximab administration. Supporting our data, th...

    Show More
  • Re:Evidence in Support of the Validity of the TNF Brake Hypothesis
    Xenofon Baraliakos

    Response to the eLetter by Maksymowych WP, entitled ?Evidence in Support of the Validity of the TNF Brake Hypothesis"

    Dear Editor,

    with great interest we read the Letter by our colleague W.Maksymowych, entitled ?Evidence in Support of the Validity of the TNF Brake Hypothesis", which commented on our paper "Continuous increase in the rate of new bone formation in patients with ankylosing spondylitis (A...

    Show More
  • Evidence in Support of the Validity of the TNF Brake Hypothesis
    Walter P. Maksymowych

    Dear Editor,

    Re: Continuous long-term anti-TNF therapy does not lead to an increase in the rate of new bone formation over 8 years in patients with ankylosing spondylitis. Baraliakos X, Haibel H, Listing J, Sieper J,Braun J. 1doi:10.1136/annrheumdis-2012-202698

    I read with interest the findings of an observational cohort study in which patients with ankylosing spondylitis (AS) receiving infliximab (IFX)...

    Show More
  • Authors' response re:Abatacept in relapsing polychondritis
    Stanford Peng

    Dear Editor,

    We were pleased to learn of Moulis et al.'s update on their experience with abatacept in three RP patients, particularly since their disease manifestations reflected the same manifestations suggested in our study to be of greatest interest for abatacept: chondritis and peripheral arthritis. Interestingly one patient achieved a complete, while another achieved only a partial, corticosteroid-sparing...

    Show More
  • Abatacept in relapsing polychondritis
    Guillaume Moulis

    Dear Editor,

    We read with great interest the open clinical trial of four relapsing polychondritis (RP) patients treated with abatacept by Peng and Rodriguez recently published in the Annals of the Rheumatic Diseases (1). Indeed, as the authors pointed out, there is rational to block T-cell pathway in this disease, though the biologic agents most used as second-line therapy after corticosteroids (CS) are pro-inflamm...

    Show More
  • Impact of gender on outcomes in ankylosing spondylitis
    Ernst Feldtkeller

    Dear Editor,

    We read with interest the article on the impact of gender on outcomes in ankylosing spondylitis [1]. In their analysis of four controlled clinical trials, the authors found a higher burden of ankylosing spondylitis (AS) in female patients and less improvement in outcome measures compared with men, "despite women having a later disease onset and shorter disease duration". They conclude that the mechanism...

    Show More
  • Are steroids required for therapy induction and relapses in lupus nephritis?
    Carlos Abud-Mendoza

    Dear Editor,

    “A finger in the wound” is put by Condon et al. in their very interesting paper treating severe lupus nephritis with rituximab and mycophenolate, additionally to i.v. methyl-prednisolone, but not long-term oral steroids, achieving a good clinical response in most patients. 1

    Rheumatologists and nephrologists have the notion that glucocorticoids are the cornerstone for the treatment of autoimmune disea...

    Show More
  • Efficacy and safety of strontium ranelate in the treatment of knee osteoarthritis: results of a double-blind randomized, placebo-controlled trial
    Jean-Yves Reginster

    Dear Editor,

    We would like to reply to the recent letter by Murphy et al(1) regarding the possible influence of obesity and weight changes on the results of the SEKOIA trial of the efficacy and safety of strontium ranelate in knee osteoarthritis.2 Obesity and overweight are recognized risk factors for osteoarthritis,3 and so it is essential to include such patients in studies of potential treatments, since they are...

    Show More
  • Is early remission associated with improved survival or is arthritis persistency associated with increased mortality in early arthritis?- comparisons with the general population
    Jessica AB van Nies

    Dear editor,

    With interest we read the article of Sciré et al.,(1) evaluating the association between remission and mortality in patients with inflammatory polyarthritis (IP). This study shows that patients achieving remission early in the disease course, have an improved survival rate compared to patients never achieving remission. Based on this observation the authors conclude that achieving remission early in t...

    Show More
  • INTERLEUKIN-6 ACTS LOCALLY ON THE GROWTH PLATE TO IMPAIR BONE GROWTH
    PF Fernandez-Vojvodich

    Dear editor,

    A recent clinical study in mothers with rheumatoid arthritis (RA) published in this journal, reported that high maternal serum levels of interleukin-6 (IL-6) is associated with low birth weight deliveries1. Low birth weight in turn is associated with impaired growth during childhood2. Interestingly, overexpression of IL-6 leads to reduced bone growth in mice3. Although the systemic effects of IL-6...

    Show More

Pages